Abstract: Novel 85Rb-enriched rubidium salt compounds of general formula 1, below and novel compounds of general formula 2, below. Compositions that contain at least one of the novel compounds and optionally further contain an antitumor drug. Methods that entail administering such compounds and compositions to treat cancer, optionally in combination with a conventional form of cancer therapy, such as chemotherapy and radiation treatment. When administered with a conventional form of cancer therapy, the compounds and compositions of the invention may be administered before, simultaneously with, or after administration of the conventional form of cancer therapy.
Type:
Grant
Filed:
March 16, 2022
Date of Patent:
November 28, 2023
Assignee:
Vector Vitale IP LLC
Inventors:
Peter Novak, Maxim Temnikov, Oleksandr Balakin
Abstract: Methods for preparing and using collagen extracts and collagen scaffolds are provided. Additionally, methods and related kits for the repair of articular tissue using the collagen material are provided.
Type:
Grant
Filed:
November 4, 2021
Date of Patent:
November 28, 2023
Assignee:
The Children's Medical Center Corporation
Abstract: Disclosed are peptides that induce an active plant response, but not a hypersensitive response, when applied to plant tissue. These peptides also preferably exhibit improved solubility, stability, resistance to chemical degradation, or a combination of these properties. Use of these peptides or fusion polypeptides, or DNA constructs encoding the same, for modulating plant biochemical signaling, imparting disease resistance to plants, enhancing plant growth, imparting tolerance to biotic stress, imparting tolerance and resistance to abiotic stress, imparting desiccation resistance to cuttings removed from ornamental plants, imparting post-harvest disease or post-harvest desiccation resistance to a fruit or vegetable, or enhancing the longevity of fruit or vegetable ripeness are also disclosed.
Abstract: ABSTRACT: A formulation of Collagen peptides with enzyme inhibitors and hyaluronic acid would increase the levels of collagen and elastin and hyaluronic acid for a long period of time, and would decrease the rate of aging, and age-related changes in the skin and other organs. During aging, the levels of these molecules decrease because of enhanced activities of their respective enzymes. Current approach has utilized collagen peptides alone to increase the levels of collagen and elastin in order to maintain healthy skin. In the absence of inhibitors of enzymes collagenase and elastase, and hyaluronic acid, the levels of collagen peptides, elastin, and hyaluronic acid would decrease. Consequently, the beneficial effects of collagen peptides alone would be reduced within a short period of time.
Abstract: Provided is a boron-containing compound suitable for the material of a blue light-emitting diode and an organic light-emitting diode using the same. The boron-containing compound has a structure represented by the formula (1): X is each independently —NR1—, —CR2R3—, —O— or —S—. In the —NR1— and —CR2R3—, R1 to R3 are each independently hydrogen, deuterium, an alkyl group having 1 to 6 carbon atoms or an aryl group having 5 to 30 core atoms, and R2 and R3 may connect with each other to form a ring. Cy1 is an aryl group having 5 to 30 core atoms. All or part of hydrogen atoms in the formula (1) may be substituted by deuterium, a halogen, an alkyl group having 1 to 6 carbon atoms, an aryl group having 5 to 30 core atoms, a substituted or unsubstituted silyl group, a substituted or unsubstituted amino group, or cyano group.
Type:
Grant
Filed:
January 5, 2021
Date of Patent:
November 21, 2023
Assignee:
FLASK CORPORATION C/O YONEZAWA CAMPUS, NATIONAL UNIVERSITY CORPORATION YAMAGATA UNIVERSITY
Abstract: The present invention generally relates to processes for the catalytic hydrogenation of halonitroaromatics. In particular, the present invention includes processes for the catalytic hydrogenation of halonitroaromatics such as 2,5-dicloronitrobenzene to 2,5-dichloroaniline over a platinum-containing catalyst. The present invention also relates to processes for producing 3,6-dichloro-2-methoxybenzoic acid.
Abstract: Disclosed are hypersensitive-response eliciting peptides that exhibit improved solubility, stability, resistance to chemical degradation, or a combination of these properties. Use of these peptides or fusion polypeptides, or DNA constructs encoding the same, for modulating plant biochemical signaling, imparting disease resistance to plants, enhancing plant growth, imparting tolerance to biotic stress, imparting tolerance and resistance to abiotic stress, imparting desiccation resistance to cuttings removed from ornamental plants, imparting post-harvest disease or post-harvest desiccation resistance to a fruit or vegetable, or enhancing the longevity of fruit or vegetable ripeness are also disclosed.
Type:
Grant
Filed:
October 29, 2020
Date of Patent:
November 21, 2023
Assignee:
PLANT HEALTH CARE, INC.
Inventors:
Zhongmin Wei, Gregory A. Zornetzer, Stephen Bornick
Abstract: Disclosed are compounds that can penetrate the mitochondrial membrane and that are able to deliver cargo (e.g., therapeutic agents) specifically to the mitochondria.
Type:
Grant
Filed:
May 6, 2019
Date of Patent:
November 14, 2023
Assignee:
OHIO STATE INNOVATION FOUNDATION
Inventors:
Dehua Pei, George Appiah Kubi, Ziqing Qian
Abstract: The present invention relates to a method of separating amino acids from an aqueous solution comprising amino acids as well as proteins and/or protein decomposition products by combining phosphoric acid with the aqueous solution to precipitate an amino acid monophosphate. The precipitate so formed may be separated from the aqueous solution and used as such, e.g. in plant fertilizer compositions. The precipitate may be redissolved in a suitable liquid, after which phosphate and amino acid may be separated following conventional methods. In either case, the present invention enables highly selective precipitation of arginine and/or lysine monophosphate as crystals.
Type:
Grant
Filed:
March 5, 2019
Date of Patent:
November 14, 2023
Assignee:
AREVO AB
Inventors:
Torgny Näsholm, Jonathan Love, Mattias Holmlund, Nils Bertil Skoglund
Abstract: Methods are disclosed including methods for crystallizing a material such as a drug. An example method may include combining a nucleation initiator, a surfactant solution, and an amorphous form of a drug to form a drug precursor dispersion/suspension. The method may also include incubating the drug precursor dispersion/suspension to allow the drug to convert from the amorphous form to a crystalline form.
Type:
Grant
Filed:
March 12, 2021
Date of Patent:
November 14, 2023
Assignee:
Boston Scientific Scimed, Inc.
Inventors:
Hongxia Zeng, Jonathan Pascal Chaky, Yen-Lane Chen
Abstract: Disclosed are a peptide compound and an application thereof, and a composition containing the peptide compound. The present invention provides a peptide compound represented by compound 3, and a pharmaceutically acceptable salt, a tautomer, a solvate, a crystal form or a prodrug thereof. The compound has good stability and good activity for Kiss1R.
Type:
Grant
Filed:
March 22, 2022
Date of Patent:
November 7, 2023
Assignee:
XDCEXPLORER (SHANGHAI) CO., LTD.
Inventors:
Yvonne Angell, Yu Wu, Yan Wang, Weimin Liu, Kin Chiu Fong, Jie Wen, Yonghan Hu
Abstract: The invention relates to protein ligation technologies, purified or recombinant peptides, methods for making peptides and proteins with covalent bonds including reversible covalent bonds such as reversible intermolecular covalent bonds, and uses thereof. In particular, this invention relates to intermolecular ester bonds, particularly reversible ester bonds between the hydroxyl and amide groups of amino acid side chains present in recombinant chimeric peptides and proteins and the use of such peptides and proteins in protein engineering, for example in the preparation of multimeric protein complexes, including functionalised multimeric protein complexes.
Type:
Grant
Filed:
November 16, 2017
Date of Patent:
November 7, 2023
Assignee:
AUCKLAND UNISERVICES LIMITED
Inventors:
Christopher John Squire, Edward Neill Baker, Paul Gary Young, Yuliana Yosaatmadja
Abstract: The invention provides novel compounds, in particular peptide and peptide analogs, which exhibit functionalities useful for treating a variety of diseases and conditions, particularly diseases and conditions relating to diabetes. The compounds of the invention are also useful for treating impaired pancreatic function, treating metabolic diseases, ex vivo islet induction, expansion and proliferation for transplantation, increasing the survival of transplanted islets in vivo, promoting neuroprotection or nerve regeneration, promoting liver regeneration, and inhibiting inflammation.
Abstract: Methods of producing a peptide containing an N-substituted amino acid or N-substituted amino acid analog of the present invention include the steps of: preparing an Fmoc-protected amino acid, an Fmoc-protected amino acid analog, or an Fmoc-protected peptide; deprotecting a protecting group which have an Fmoc skeleton of the Fmoc-protected amino acid and such by using a base; and forming an amide bond by adding a new Fmoc-protected amino acid and such; and when the peptide is produced by a solid-phase method, the obtained peptide is cleaved off from the solid phase under conditions of weaker acidity than TFA. Furthermore, at least one side chain of the obtained peptide has a protecting group that is not deprotected under basic conditions and is deprotected under conditions of weaker acidity than TFA.
Abstract: The invention relates to a process for the preparation of Melphalan (4-[bis(2-5 chloroethyl)amino]-L-phenylalanine of formula (I) said process comprising the reaction of a 4-amino-L-phenylalanine protected at the carboxy and amino aminoacidic groups with an agent able to convert the aromatic amino group into a group of formula: —N(CH2CH2OS(O)nO—)2, wherein n is 1 or 2 followed by conversion of the ?N(CH2CH2OS(O)nO—)2 group into a —N(CH2CH2Cl)2 group. The invention also provides novel intermediates useful for the preparation of Melphalan.
Type:
Grant
Filed:
December 21, 2020
Date of Patent:
October 17, 2023
Assignee:
Indena S.P.A.
Inventors:
Pietro Allegrini, Andrea Bonetti, Marco Molinari, Andrea Gambini
Abstract: A preparation method according to the present invention makes it possible to industrially produce large amounts of highly pure optically active tert-butyl 3-methyl-4-oxopiperidine-1-carboxylate in high yield by use of commercially available reagents and solvents. In addition, the use of novel intermediates according to the present invention makes it possible to produce highly pure optically active tert-butyl 3-methyl-4-oxopiperidine-1-carboxylate in high yield.
Type:
Grant
Filed:
January 7, 2022
Date of Patent:
October 10, 2023
Inventors:
Jae Hong Kweon, Eun Sun Kim, Hyuk Woo Lee, Dong Hyun Ko, Chae Young Ryu, Kwang Do Choi, SeungPyeong Heo
Abstract: The present disclosure provides a high-activity memory-improving derivative peptide and use thereof in preparation of memory-improving medicaments, health care products or foods, and belongs to the field of biotechnology. According to the present disclosure, proline 3 (Pro3) of a pine nut high-activity memory-improving peptide, WYPGK, is completely substituted with common amino acids to obtain 19 derivative peptides, and the derivative peptides are subjected to molecular docking with mitochondrial deacetylase sirtuin 3 and are screened by binding energy to obtain derivative peptides WYEGK, WYKGK, WYSGK, and WYFGK; solid-phase chemical synthesis is conducted by a peptide synthesizer; the derivative peptides are purified by reversed phase high performance liquid chromatography (RP-HPLC) and prepared by electrospray ionization mass spectrometry (ESI-MS). Morris water maze for scopolamine-induced memory impairment model mice demonstrates that the derivative peptides have high memory-improving activity.
Type:
Grant
Filed:
September 29, 2022
Date of Patent:
October 10, 2023
Assignee:
JILIN AGRICULTURAL UNIVERSITY
Inventors:
Weihong Min, Hongyan Lu, Chunlei Liu, Ji Wang, Li Fang
Abstract: The present invention is directed to a method of producing active pharmaceutical ingredients (APIs). The method includes subjecting a reaction mixture with an API precursor to solvent extraction to produce a reactant stream with the API precursor. The method includes concentrating the API precursor in the reactant stream using at least one membrane. The method includes carrying out a reaction in a membrane reactor. The method includes separating the API precursor from the reaction stream using a separator. The method includes crystallizing the API precursor using a crystallizer to produce APIs.